Teva - Celltrion and Teva announce FDA approval of HERZUMA® (trastuzumab-pkrb)
Celltrion and Teva Pharmaceutical announced that the FDA has approved HERZUMA® (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to HERCEPTIN® (trastuzumab) for Adjuvant Breast Cancer of HER2 and Metastatic Breast Cancer. December 14, 2018